{"entity":{"id":"nct04733183","kind":"trial","name":"Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma","aka":[],"tldr":"A phase 2 trial of Dacarbazine in sarcomas, run by Philogen S.p.A., active and no longer recruiting.","summary":"Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma is a phase 2 interventional study registered as NCT04733183 by Philogen S.p.A., with 98 participants planned, started 2020-08-28 and due to reach its primary completion in 2025-12. Interventions recorded: Dacarbazine, onfekafusp alfa. Conditions listed: Soft Tissue Sarcoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04733183","url":"https://clinicaltrials.gov/study/NCT04733183"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["dacarbazine"],"companies":["philogen-s-p-a"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04733183","phase":"2","setting":"A Randomized Study to Investigate the Efficacy and Safety of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma","sponsor":"Philogen S.p.A.","enrolled":98,"outcomes":[]},"route":"/trials/nct04733183/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"drug":[{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"}],"company":[{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/"}]}}